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Abstract: We report on the synthesis of 4-hydroxycoumarin dimers 1–15 bearing an aryl 
substituent on the central linker and fused benzopyranocoumarin derivatives 16–20 and on 
their in vitro broad anti-DNA and RNA virus activity evaluations. The chemical identities 
and structure of compounds 1–20 were deduced from their homo- and heteronuclear NMR 
measurements whereas the conformational properties of 5, 14 and 20 were assessed by the 
use of 1D difference NOE enhancements. Unequivocal proof of the stereostructure of 
compounds 7, 9, 16 and 18 was obtained by single crystal X-ray diffraction method. The 
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X-ray crystal structure analysis revealed that two 4-hydroxycoumarin moieties in the  
4-trifluoromethylphenyl- and 2-nitrophenyl derivatives (compounds 7 and 9, respectively) 
are intramolecularly hydrogen-bonded between hydroxyl and carbonyl oxygen atoms. 
Consequently, the compounds 7 and 9 adopt conformations in which two 4-hydroxy-
coumarin moieties are anti-disposed. Antiviral activity evaluation results indicated that the 
4-bromobenzylidene derivative of bis-(4-hydroxycoumarin) (compound 3) possesses 
inhibitory activity against HSV-1 (KOS), HSV-2 (G), vaccinia virus and HSV-1 TK- KOS 
(ACVr) at a concentration of 9–12 μM and at a minimum cytotoxic concentration (MCC) 
greater than 20 μM. Compounds 4–6, 8, and 20 were active against feline herpes virus 
(50% effective concentration, EC50 = 5–8.1 μM), that is at a 4-7-fold lower concentration 
than the MCC. 
Keywords: 4-hydroxycoumarin; benzopyranocoumarin; antiviral activity; 1H/13C-NMR 
conformational study; X-ray diffraction 
 
1. Introduction 
Numerous experimental studies indicate that natural and synthetic coumarins (2H-1-benzopyran-2-
ones) and their derivatives are endowed with excellent chemical reactivity and different bioactivity. 
Thus, the natural coumarins play an important role in plant biochemistry and physiology. They act as 
antioxydants, enzyme inhibitors and precursors of toxic substances. They are also involved in the 
actions of plant growth hormones and growth regulators, the control over the respiration and 
photosynthesis, as well as in the defense against various infections [1]. Although most of the existing 
natural coumarins have been isolated from higher plants, some of them have been discovered in 
microorganisms, e.g., aminocoumarin antibiotics: Novobiocin, coumermycin A1 and chlorobiocin 
(produced by the actinomycete Streptomyces niveus) [2]. 
Synthetic coumarin derivatives have been obtained by chemical modification of the coumarin ring. 
As a substitution can conceptually occur at any of the six available sites of the basic molecule, these 
compounds are widely variable in structure and activity. The biological activities of coumarin 
derivatives, in particular their therapeutic application as anticoagulant and antibacterial agents [3], has 
stimulated further interest for the synthesis of this class of compounds. A variety of synthesized 
coumarin derivatives have been experimentally shown to exert pharmacological activities including 
inhibition of platelet aggregation, cytochrome P450, and steroid 5-α-reductase. 
They have also been shown to exert efficient anti-proliferative, antifungal, anti-psoriasis, anti-
inflammatory, as well as antiviral activities [4-8]. The interest in coumarins has recently increased 
significantly because it was found that they inhibit HIV (human immunodeficiency virus), by affecting 
integrase and reverse transcriptase, which play a critical role in the replicative cycle of HIV [9-11]. 
The present study is focused on the antiviral activity evaluation of the benzylidene-bis- 
(4-hydroxycoumarin) derivatives 1–15 and 3-[6-oxo-(1H)-benzopyrano[4,3-b]benzopyran-7-yl]-4-
hydroxycoumarin derivatives 16–20 (Figure 1). 
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Figure 1. (a) The benzylidene-bis-(4-hydroxycoumarin) derivatives 1–15; (b) 3-[6-oxo-
(1H)-benzopyrano[4,3-b]benzopyran-7-yl]-4-hydroxycoumarin derivatives 16–20. 
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2. Results and Discussion 
2.1. Chemistry 
The benzylidene-bis-(4-hydroxycoumarin) derivatives 1–15 and fused benzopyranocoumarin 
derivatives 16–20 were prepared by a sequence of reactions displayed in the Scheme 1. In the first step 
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of the synthesis the aldol condensation of 4-hydroxycoumarin (4-HC) with an appropriately 
substituted aldehyde linker followed by dehydration of aldol product (AL) gave a chromone (CR). 
Subsequent in situ reaction of the chromon with 4-hydroxycoumarin already present in excess in the 
reaction mixture gave dimeric coumarin derivatives 1–15 bearing an aryl substituent in the central 
methylene linker. In contrast, the chromone derivatives containing an ortho-substituted phenyl moiety 
(R1 = Cl, F, OH, OCH3) gave under spontaneous cyclization the fused benzopyranocoumarin 
derivatives 16–20. The compounds 1 [11,14,16], 2 [11,13,14], 4 [14], 5 [14], 6 [13], 8 [14], 9 [11,14], 
10 [14], 11 [14], 12 [11,14] and 16 [17,18] that have been described previously were also synthesized 
for their antiviral activity evaluations. 
Scheme 1. Synthesis of coumarin-dimer derivatives with variously substituted aryl central 
linkers (1–15) and fused benzopyranocoumarin derivatives 16–20. Reagents and 
conditions: (i) EtOH, heating under reflux for 24 h. 
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2.2. NMR Assignment and Conformational Study 
The chemical identities and structures of 1–20 were confirmed by homo- and heteronuclear NMR 
measurements. 1H-, 13C- and 19F-NMR chemical shifts are reported in the Experimental section. 
Proton-decoupled 13C-NMR spectra showed C–F coupling constants that enabled straightforward 
identification of fluorinated carbon atoms and their neighbors. In the 1H spectrum of 1, 2, 4 and 10, 
which were dissolved in non-polar solvents, well resolved hydroxyl protons were observed in the range 
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from δ 11.3 to 11.5 ppm (see Experimental section for details). The strongly deshielded signals suggest 
that OH protons are most probably involved in hydrogen bond formation. In addition, two set of  
1H-NMR signals were observed for H5 and H5” protons which indicates a slight difference in 
magnetic environment for otherwise symmetrical moieties. Furthermore, hydroxyl protons, which were 
observed between δ 11.8 and 12.3 ppm for benzopyranocoumarin derivatives 16, 18 and 20, are most 
likely involved in hydrogen bonds. 
Hydrogen bonds described above partially determined conformational preferences of the studied 
compounds. Conformational properties of 5, 14 and 20 were assessed with the use of 1D NOE 
difference experiments. Key NOE enhancements are shown in Figure 2. The saturation of H* in 5 
resulted in weak NOE at H6' (1.5%) and 2'-OCH3 (0.8%, Figure 2a). 
Figure 2. Key NOE enhancements in 5 (a) and 14 (b). Dotted lines present hydrogen bonds. 
 
Likewise, the saturation of H* in 14 gave moderate NOE at H6' (3.7%) and weak NOE at 2'-OCH3 
(0.8%). These observations suggested nonrestricted rotation along C*–C1' bonds in 5 and 14. No 
NOEs indicative of relative orientations of individual heterocyclic moieties were observed for 20. 
Interestingly, benzopyranocoumarin derivatives 16, 18 and 20 showed two sets of signals in the 1H 
spectrum for coumarin protons. One set of 1H signals (H5-H8 protons) exhibited broader line-widths 
with respect to multiplets attributed to H5”-H8” protons. This phenomenon was studied in more detail 
for 20 by variable temperature experiments in the range from 298 to 358 K. As an example, broad 
multiplet at δ 8.00 ppm corresponding to H5 becomes sharper at higher temperatures (Figure 3). This 
suggests that rotation along C*–C3 bond is restricted at lower temperatures, most likely due to formation of 
hydrogen bond between the C4-OH and C2” carbonyl group (for enumeration of atoms c.f. Figure 2). 
2.3. X-Ray Crystal Structure Study 
In 7 (Figure 4a) and 9 (Figure 4b), two 4-hydroxycoumarin moieties are linked through a methylene 
bridge on which one hydrogen atom has been replaced with a phenyl ring bearing p-trifluoromethyl 
and o-nitro groups, respectively. In general, the geometry of the molecules agrees with closely related 
structures [19-21]. 
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Figure 3. 1H-NMR spectra of 20 dissolved in DMSO-d6 at temperatures in the range 
from 298 to 358 K. 
 
Figure 4. A view of 7 (a) and 9 (b), with the atom-numbering scheme. Displacement 
ellipsoids for non-hydrogen atoms are drawn at the 20% and 30% probability level for 7 
and 9, respectively. Intramolecular hydrogen bonds are indicated by dashed lines. 
 
The exocyclic bond angles around C3 atom in 7 and 9 differ by even 11.7o and 11.6o, respectively. 
The corresponding angles about C3' atom of the coumarin ring differ by only 5.6o in 7 and 4.0o in 9. 
This asymmetry, which is also found in similar structures, may be a consequence of steric crowding 
within the molecules. Because of the same reason all principal bond angles about C11 are widened 
over normal tetrahedral values, ranging from 112.5(2) to 115.4(2)° in 7 and 111.75(12) to 115.63(12)° 
in 9. The coumarin rings are slightly distorted from planarity, with two planes inclined at 57.83(11)° 
and 59.55(5)° to each other in 7 and 9, respectively. 
The 4-hydroxycoumarin moieties are intramolecularly hydrogen bonded between hydroxyl and 
carbonyl oxygen atoms in both structures (see Figures 4a and 4b and Table S1 in ESI), thus forming 
two eight-membered rings. Thus, compounds 7 and 9 adopt a conformation in which two  
4-hydroxycoumarin moieties are anti-disposed. Benzylidene bis (4-hydroxycoumarin) derivatives 7 
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and 9 form supramolecular self-assemblies by C−H···O hydrogen bonds (Figures S1 and S2, see ESI) 
in which infinite chains are extended by one F···F interaction between trifluoromethyl fluorine atoms in 
7 [F2···F2i = 2.934(5) Å; (i): −x, −y, −z] and one π···π interaction in 9. The distance between the ring 
centroids of coplanar C5'–C10' rings [α = 0o] in 9 is 3.6832(12) Å, the planes are separated by 
3.5132(8) Å and centroids offset is ca. 1.11 Å. 
Cyclized compound 16 (Figure 5a) crystallized with two independent molecules, two ethanol 
molecules and one water molecule in the asymmetric unit in monoclinic space group P 21/c. The bond 
lengths in two independent molecules of 16, denoted as A and B, are within 2σ values, and agree very 
well with the corresponding ones in 18 (Figure 5b). 
Figure 5. A view of 16 (a) and 18 (b), with the atom-numbering scheme. For clarity, only 
one independent molecule of 16 is shown. Displacement ellipsoids for non-hydrogen atoms 
are drawn at the 30% probability level. Intramolecular hydrogen bond in 18 is indicated by 
dashed line. 
 
The main structural difference between these two structures is in orientation of the coumarin rings. 
The coumarin ring in 18 is flipped by approximately 180o compared to the situation in 16, and such 
ring orientation enables O−H···O intramolecular hydrogen bond formation (Table S1, see ESI). Two 
independent molecules of 16, two ethanol molecules and water molecule are linked by six O−H···O 
and four C−H···O hydrogen bonds into three-dimensional network (Figure S3, see ESI). Two C−H···π 
interactions participate also in supramolecular aggregation. On the contrary, only one hydrogen bond 
of C−H···O type links the molecules of 18, thus forming discrete centrosymmetric dimers via  
20-membered rings (Figure S4, see ESI). 
2.4. Biological Activity Results 
Antiviral activity.-Compounds 1–20 were evaluated for their inhibitory activities against herpes 
simplex virus type 1 and 2 [HSV-1 (KOS), HSV-2 (G)], vaccinia virus, vesicular stomatitis virus and 
herpes simplex virus-1 TK− KOS (ACVr) in HEL cell cultures. Their activities were compared with 
those of brivudin [(E)-5-(2-bromovinyl)-2’-deoxyuridine], cidofovir [(S)-1-[3-hydroxy-2-(phosphonyl-
methoxy)propyl]cytosine], acyclovir [9-(3-hydroxyethoxymethyl)guanine] and gancyclovir [9-[(1,3-
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dihydroxy-2-propoxy)methyl]guanine] (Table 1, only data for the selected number of compounds 1, 4–6, 
8, 9 and 20 are shown). 
Of all evaluated compounds only the 3-bromobenzylidene derivative 3 of bis(4-hydroxycoumarin) 
showed potentially interesting inhibitory activity against HSV-1 (KOS), HSV-2 (G), vaccinia virus and 
HSV-1 TK− KOS (ACVr) in the range of 9–12 μM at a minimum cytotoxic concentration (MCC) 
greater than 20 μM, whereas compound 19 showed only slight activity against HSV-1 (KOS), HSV-2 
(G) and HSV-1 TK− KOS (EC50 = 45–50 μM) in human embryonic lung HEL cell cultures and no 
cytotostatic activity at 100 µM (Table 1, data taken together from two independent experiments). 
Evaluation of compounds 1–20 on Feline corona virus (FIPV) and Feline herpes virus activity and 
cytotoxicity in Crandell-Rees feline kidney (CRFK) cell cultures showed that the benzylidene-bis-(4-
hydroxycoumarin) derivatives 1, 4–6, 8 and 9, and the benzopyranocoumarin derivative 20 exerted 
anti-FIPV activity (EC50 = 7.2–10 μM) in CRFK cell cultures. Such activity is within the same 
magnitude as that of the plant lectin Urtica dioica agglutinin (UDA) [10] (EC50 = 6 μM) but less active 
than Hyppeastrum hybride agglutinin (HHA) [12] (EC50 = 0.38 μM). However it should be noted that 
the novel compounds showed cytostatic activities at concentrations that are only 4-5-fold higher than 
the antiviral active concentrations and therefore, it can be questioned whether the antiviral effect 
observed represents a direct antiviral effect or elicited indirectly by the cytotoxic activity of the test 
compounds. Similarly, the compounds 4–6, 8 and 20 exhibited anti-Feline Herpes Virus activity  
(EC50 = 5–8.1 μM) the MCC were only 4-7-fold higher than the EC50 values (Table 2, only selected 
data for compounds 1, 4–6, 7, 8 and 20 are shown). 
Table 1. Cytotoxicity and antiviral activity of coumarin derivatives 3, 7, 8, 11, 13–15, 19 
and 20 in HEL cell cultures. 
Compound 
MCC a 
(μM) 
EC50 b (μM) 
HSV-1 
(KOS) 
HSV-2 
(G) 
Vaccinia 
virus 
Vesicular 
stomatitis virus
HSV-1 
TK− KOS ACVr
3 >20 9 9 11 >20 9 
7 20 >4 >4 >4 >4 >4 
8 100 >20 >20 >20 >20 >20 
11 100 >20 >20 >20 >20 >20 
13 100 >20 >20 >20 >20 >20 
14 >100 >100 >100 >100 >100 >100 
15 >100 >100 >100 >100 >100 >100 
19 >100 50 45 >100 >100 50 
20 100 >20 >20 >20 >20 >20 
Brivudin >250 0.06 182 3.2 >250 50 
Cidofovir >250 0.9 1.5 7.9 >250 1.5 
Acyclovir >250 0.30 0.35 >250 >250 20 
Ganciclovir >100 0.025 0.030 >100 >100 0.1 
a Minimum cytotoxic concentration, as determined by examining the microscopically visible 
morphological alteration of the cell cultures; b 50% Effective concentration, or concentration 
producing 50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell 
viability with the colorimetric formazan-based MTS assay. 
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Table 2. Cytotoxicity in CRFK cell cultures and anti-Feline Corona Virus (FIPV) and  
anti-Feline Herpes Virus activity of coumarin derivatives 1, 4–6, 8, 9 and 20. 
Compound 
Minimum cytotoxic 
conc. in CRFK cell 
cultures (CC50) a (μM) 
EC50 b (μM) 
Feline Corona Virus 
(FIPV) 
Feline 
Herpes Virus
1 43 7.5 9.1 
4 45 9.1 7.6 
5 36 7.5 5.0 
6 39 7.7 8.1 
8 41 8.5 6.9 
9 34 8.3 14 
20 27 6.4 7.1 
HHA > 2 0.34 0.15 
UDA >10 4.2 7.1 
Ganciclovir >100 >100 4.9 
a 50% Cytotoxic concentration, as determined by measuring the cell viability by the colorimetric 
formazan-based MTS assay; b 50% Effective concentration, or compound concentration producing 
50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability 
with the colorimetric formazan-based MTS assay. 
Compounds 1–20 were also evaluated for their cytotoxicity and antiviral activities against 
Coxsackie virus B4 and respiratory syncytial virus (RSV) in HEL cell cultures; parainfluenza-3 virus, 
reovirus-1, Sindbis virus, Coxsackie virus B4 and Punta Toro virus in Vero cell cultures; and influenza 
virus subtypes A H1N1 and H3N2, and influenza virus B. No specific antiviral effects (i.e., antivirally 
effective concentration >5-fold lower than the minimal cytotoxic concentration) were noted for any of 
the evaluated compounds. 
3. Experimental 
3.1. General Methods 
Melting points (uncorrected) were determined with Büchi melting point B-545. Precoated Merck 
silica gel 60F-254 plates were used for thin-layer chromatography (TLC) and the spots were detected 
under UV light (254 nm). Solvent system used for TLC was chloroform:methanol = 9:1. Mass spectra 
were recorded with an Autospec: ESI/Q-TOF Premier instrument. 1H-NMR spectra were recorded  
at 600 MHz, in deuterated DMSO-d6, on Bruker (UXNMR/XwinNMR) spectrometer, using 
tetramethylsilane (TMS) as internal reference. 1D and 2D NMR spectra were recorded at 25 °C on 
Varian Unity Inova 300 spectrometers. 1H and 13C chemical shifts were referred to residual signal of 
CDCl3, CD2Cl2 and DMSO-d6 (δTMS 0.0 ppm). 19F chemical shifts were referenced externally with 
respect to CCl3F (δ 0.0 ppm). 1H, 13C and 19F-NMR resonances were assigned on the basis of signal 
intensities and multiplicities in 1D spectra as well as correlation signals in 2D 1H-1H COSY, 1H-13C 
HSQC and 1H-13C HMBC NMR spectra. Elemental analyses were performed in the Central Analytic 
Service, Rudjer Bošković Institute Zagreb, Croatia, using a Perkin Elmer 2400 Elemental Analyser. 
The infrared spectra were obtained from potassium bromide triturate containing 0.5% of the product on a 
Perkin-Elmer 1000 FT-IR spectrophotometer. All data were recorded at 25 °C unless specified otherwise. 
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3.2. Procedures for the Preparation of Compounds 
3.2.1. The compounds 1–20 were prepared by the following general procedure 
4-Hydroxycoumarin (2 mmol) was dissolved in hot ethanol (6 mL), the corresponding aldehyde  
(1 mmol) was added, and the reaction mixture was refluxed for 24 h. After cooling to room 
temperature, the solid was filtered off and crystallized to give the product benzylidene-bis-(4-
hydroxycoumarin) derivatives 1–15 and 3-[6-oxo-(1H)-benzopyrano[4,3-b]benzopyran-7-yl]-4-
hydroxycoumarin derivatives 16–20 (Figure 1). 
3.2.2. Compound data 
3,3'-(Benzilidene)-bis-[4-hydroxycoumarin] (1) [11,14,16]. Yield 77.5%; mp 233.3 °C; IR (KBr)  
(ν, cm−1): 2901 (CH); 1658 (C=O); 1600, 1584, 1497, 1450 (C=C ar.); 1199 (OH); 1H-NMR (CDCl3): 
δ 6.11 (H*, s, 1H), 7.23 (H2'/H6', m, 2H), 7.27 (H4', m, 1H), 7.33 (H3'/H5', m, 2H), 7.38 (H6/H6", m, 
2H), 7.42 (H8/H8", m, 2H), 7.63 (H7/H7", m, 2H), 8.00 (H5/H5", d, J = 7.3, 1H), 8.08 ppm (H5/H5", 
d, J = 6.8, 1H), 11.41 (OH, b, 2H); 13C-NMR (CDCl3): δ 36.16 (C*), 103.90/105.63 (C3/C3"), 116.63 
(C8/C8"), 116.91 (C10/C10"), 124.39 (C5/C5"), 124.88 (C6/C6"), 126.47 (C2'/C6'), 126.87 (C4'), 
128.63 (C3'/C5'), 132.85 (C7/C7"), 135.17 (C1'), 152.29/152.53 (C9/C9"), 164.60/165.80 (C4/C4"), 
166.87/169.31 ppm (C2/C2"); ES-MS m/z 413 [M−H]. 
3,3'-(4-Bromobenzylidene)-bis-[4-hydroxycoumarin] (2) [11,13,14]. Yield 74%; mp 267.2 °C; IR 
(KBr) (ν, cm−1): 3276 (OH), 2730 (CH), 1772 (C=O), 1668 (C=C–C=O), 1604, 1564, 1488, 1454 
(C=C), 646 (C–Br); 1H-NMR (CDCl3): δ 6.02 (H*, s, 1H), 7.10 (H2'/H6', m, 2H), 7.38 (H6/H6", m, 
2H), 7.41 (H8/H8", m, 2H), 7.44 (H3'/H5', m, 2H), 7.64 (H7/H7", m, 2H), 7.99 (H5/H5", d, J = 7.7, 1H), 
8.07 (H5/H5", d, J = 7.3, 1H), 11.32 ppm (OH, s, 1H), 11.54 (OH, s, 1H); 13C-NMR (CDCl3): δ 35.87 
(C*), 103.62/105.18 (C3/C3"), 116.33/116.67 (C10/C10"), 116.69 (C8/C8"), 120.80 (C4'), 124.41 
(C5/C5"), 125.00 (C6/C6"), 128.33 (C2'/C6'), 131.70 (C3'/C5'), 133.04 (C7/C7"), 134.41 (C1'), 
152.28/152.53 (C9/C9"), 164.64/166.03 (C4/C4"), 166.84/169.21 ppm (C2/C2"); ES-MS m/z 491 
[M−H]. Elemental analysis. Calc. for C25H15O6Br: C 61.12, H 3.08, Found: C 61.07, H 3.13. 
3,3'-(3-Bromobenzylidene)-bis-[4-hydroxycoumarin] (3). Yield 83%; mp 287 °C; IR (KBr) (ν, cm−1): 
2918 (CH), 1774 (C=O), 1648 (C=C–C=O), 1610, 1568, 1498, 1452 (C=C), 1196 (OH), 970 (C–Br); 
1H-NMR (DMSO-d6): δ 6.31 (H*, d, J = 0.9, 1H), 7.14 (H6', m, 1H), 7.18 (H5', m, 1H), 7.26 (H2', m, 
1H), 7.29 (H6/H6", m, 2H), 7.32 (H4', m, 1H), 7.33 (H8/H8", m, 2H), 7.57 (H7/H7", m, 2H), 7.88 ppm 
(H5/H5", dd, J = 7.9, 1.7, 2H); 13C-NMR (DMSO-d6): δ 36.02 (C*), 103.32 (C3/C3"), 115.80 
(C8/C8"), 118.75 (C10/C10"), 121.46 (C3'), 123.41 (C6/C6"), 124.03 (C5/C5"), 126.00 (C6'), 128.23 
(C4'), 129.26 (C2'), 130.12 (C5'), 131.58 (C7/C7"), 144.40 (C1'), 152.37 (C9/C9"), 164.49 (C2/C2"), 
166.51 ppm (C4/C4"); ES-MS m/z 491 [M−H]. Elemental analysis. Calc. for C25H15O6Br: C 61.12, H 
3.08, Found: C 61.24, H 3.11. 
3,3’-(4-Chlorobenzylidene)-bis-[4-hydroxycoumarin] (4) [14]. Yield 82%; mp 256.7 °C; IR (KBr) (ν, 
cm−1): 2858 (CH), 1828 (C=O), 1668 (C=C–C=O), 1604, 1562, 1490, 1454 (C=C), 1182 (OH), 706  
(C–Cl); 1H-NMR (CDCl3): δ 6.04 (H*, s, 1H), 7.16 (H2'/H6', m, 2H), 7.29 (H3'/H5', m, 2H), 7.39 
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(H6/H6", m, 2H), 7.41 (H8/H8", m, 2H), 7.64 (H7/H7", m, 2H), 8.00 (H5/H5", d, J = 7.7, 1H), 8.07 
(H5/H5", d, J = 7.7, 1H), 11.32 (OH, b, 1H), 11.54 ppm (OH, b, 1H); 13C-NMR (CDCl3): δ 35.80 
(C*), 103.69/105.25 (C3/C3"), 116.34/116.81 (C10/C10"), 116.67 (C8/C8"), 124.42 (C5/C5"), 124.99 
(C6/C6"), 127.97 (C2'/C6'), 128.77 (C3'/C5'), 132.73 (C4'), 133.04 (C7/C7"), 133.84 (C1'), 
152.28/152.53 (C9/C9"), 164.65/166.01 (C4/C4"), 166.85/169.21 ppm (C2/C2"); ES-MS m/z 447 
[M−H]. Elemental analysis. Calc. for C25H15O6Cl: C 67.19, H 3.38, Found: C 67.16, H 3.49. 
3,3'-(2-Methoxybenzylidene)bis[4-hydroxycoumarin] (5) [14]. Yield 82%; mp 254.7 °C; IR (KBr) (ν, 
cm−1): 3030 (C–CH); 2898 (CH); 1670 (C=C–C=O), 1604, 1566, 1498, 1450 (C=C), 1192 (OH), 660 
(C–Cl); 1H-NMR (DMSO-d6): δ 3.57 (OCH3, s, 3H), 6.25 (H*, s, 1H), 6.84 (H5', m, 1H), 6.89 (H3', d, 
J = 7.9, 1H), 7.16 (H6', m, 1H), 7.17 (H4', m, 1H), 7.32 (H6/H6", m, 2H), 7.36 (H8/H8", d, J = 8.0, 
2H), 7.58 (H7/H7", m, 2H), 7.90 ppm (H5/H5", dd, J = 7.9, 1.2, 2H); 13C-NMR (DMSO-d6): δ 32.93 
(C*), 55.51 (OCH3), 104.80 (C3/C3"), 110.94 (C3'), 115.91 (C8/C8"), 117.54 (C10/C10"), 119.85 
(C5'), 123.60 (C5/C5"), 123.67 (C6/C6"), 127.29 (C4'), 128.22 (C6'), 128.29 (C1'), 131.63 (C7/C7"), 
151.98 (C9/C9"), 157.34 (C2'), 163.63 (C4/C4"), 163.99 ppm (C2/C2"); ES-MS m/z 447 [M−H]. 
3,3'-(4-Fluorobenzylidene)-bis-[4-hydroxycoumarin] (6) [13]. Yield 86%; mp 214.5 °C; IR (KBr) (ν, 
cm−1): 2858 (CH), 1774 (C=O), 1675 (C=C–C=O), 1608, 1534, 1508, 1454 (C=C), 1188 (OH), 1030 
(C–F); 1H-NMR (DMSO-d6): δ 6.31 (H*, m, 1H), 7.03 (H3'/H5', m, 2H), 7.17 (H2'/H6', m, 2H), 7.31 
(H6/H6", m, 2H), 7.35 (H8/H8", m, 2H), 7.58 (H7/H7", m, 2H), 7.89 ppm (H5/H5", dd, J = 7.9, 1.7, 
2H); 13C-NMR (DMSO-d6): δ 35.48 (C*), 104.01 (C3/C3"), 114.58 (C3'/C5', d, JCF = 20.9), 115.88 
(C8/C8"), 118.23 (C10/C10"), 123.59 (C6/C6"), 123.93 (C5/C5"), 128.52 (C2'/C6', d, JCF = 7.7), 
131.76 (C7/C7"), 136.34 (C1', d, JCF = 2.8), 152.26 (C9/C9"), 160.42 (C4', d, JCF = 241.2), 164.66 
(C2/C2"), 165.68 ppm (C4/C4"). 19F-NMR (DMSO-d6): δ –117.92 ppm (C4'-F, m); ES-MS m/z 431 
[M−H]. 
3,3'-(4-Trifluoromethylbenzylidene)-bis-[4-hydroxycoumarin] (7). Yield 72%; mp 271.3 °C; IR (KBr) 
(ν, cm−1): 2918 (CH), 1778 (C=O), 1652 (C=C–C=O), 1604, 1568, 1504, 1454 (C=C), 1470 (C–C), 
1198 (OH), 1028 (C–F); 1H-NMR (DMSO-d6): δ 6.34 (H*, d, J = 0.9, 1H), 7.27 (H6/H6", m, 2H), 7.31 
(H8/H8", m, 2H), 7.34 (H2'/H6', d, J = 8.4, 2H), 7.55 (H7/H7", m, 2H), 7.55 (H3'/H5', d, J = 8.4, 2H), 
7.85 ppm (H5/H5", dd, J = 7.8, 1.5, 2H); 13C-NMR (DMSO-d6): δ 36.33 (C*), 103.18 (C3/C3"), 
115.70 (C8/C8"), 119.07 (C10/C10"), 123.25 (C6/C6"), 124.07 (C5/C5"), 124.58 (CF3, q, JCF = 271.7), 
124.77 (C3'/C5', q, JCF = 4.2), 125.92 (C4', q, JCF = 31.6), 127.44 (C2'/C6'), 131.43 (C7/C7"), 146.86 
(C1'), 152.44 (C9/C9"), 164.44 (C2/C2"), 166.95 ppm (C4/C4"); 19F-NMR (DMSO-d6): δ –60.03 ppm 
(CF3, s); ES-MS m/z 481 [M−H]. Elemental analysis. Calc. for C26H15O6F3: C 65.01, H 3.15, F 11.86, 
Found: C 65.11, H 3.25, F 11.97. 
3,3'-(4-Nitrobenzylidene)-bis-[4-hydroxycoumarin] (8) [14]. Yield 84%; mp 236.3 °C; IR (KBr) (ν, 
cm−1): 2858 (CH), 1794 (C=O); 1656 (C=C–C=O), 1600, 1562, 1492, 1454 (C=C); 1390, 1518 (NO2); 
1196 (OH); 1H-NMR (DMSO-d6): δ 6.38 (H*, m, 1H), 7.28 (H6/H6", m, 2H), 7.33 (H8/H8", m, 2H), 
7.40 (H2'/H6', m, 2H), 7.57 (H7/H7", m, 2H), 7.86 (H5/H5", dd, J = 7.8, 1.5, 2H), 8.08 ppm (H3'/H5', 
m, 2H); 13C-NMR (DMSO-d6): δ 36.70 (C*), 103.13 (C3/C3"), 115.78 (C8/C8"), 118.83 (C10/C10"), 
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123.17 (C3'/C5'), 123.36 (C6/C6"), 124.07 (C5/C5"), 128.00 (C2'/C6'), 131.60 (C7/C7"), 145.46 (C4'), 
150.48 (C1'), 152.44 (C9/C9"), 164.36 (C2/C2"), 166.79 ppm (C4/C4"); ES-MS m/z 458 [M−H]. 
3,3’-(2-Nitrobenzylidene)-bis-[4-hydroxycoumarin] (9) [11,14]. Yield 73.5%; mp 202 °C; IR (KBr) (ν, 
cm−1): 2874 (CH), 1816 (C=O); 1656 (C=C–C=O), 1604, 1568, 1494, 1452 (C=C), 1524, 1355 (NO2), 
1199 (OH); 1H-NMR (DMSO-d6): δ 6.52 (H*, s, 1H), 7.27 (H6/H6", m, 2H), 7.31 (H8/H8", m, 2H), 
7.39 (H4', m, 1H), 7.40 (H6', m, 1H), 7.53 (H5', m, 1H), 7.55 (H7/H7", m, 2H), 7.64 (H3', m, 1H), 7.83 
ppm (H5/H5", dd, J = 7.8, 1.5, 2H); 13C-NMR (DMSO-d6): δ 34.18 (C*), 103.07 (C3/C3"), 115.84 
(C8/C8"), 118.24 (C10/C10"), 123.37 (C6/C6"), 123.86 (C5/C5"), 123.98 (C3'), 126.96 (C4'), 129.80 
(C6'), 131.54 (C7/C7"), 131.84 (C5'), 134.89 (C1'), 149.48 (C2'), 152.35 (C9/C9"), 163.32 (C2/C2"), 
165.84 ppm (C4/C4"); ES-MS m/z 458 [M−H] (Elemental analysis. Calc. for C25H15O8N: C 65.65, H 
3.31, N 3.06, Found: C 65.59, H 3.28, N 3.06. 
3,3’-(4-Methoxybenzylidene)-bis-[4-hydroxycoumarin] (10) [14]. Yield 80%; mp 248.4 °C; IR (KBr) 
(ν, cm−1): 2902 (CH); 1652 (C=C–C=O), 1604, 1564, 1496, 1454 (C=C), 1360 (CH3O), 1194 (OH);  
1H-NMR (CD2Cl2): δ 3.79 (OCH3, s, 3H), 6.03 (H*, s, 1H), 6.85 (H3'/H5', m, 2H), 7.13 (H2'/H6', m, 
2H), 7.43 (H6/H6", m, 2H), 7.43 (H8/H8", m, 2H), 7.66 (H7/H7", m, 2H), 8.02 (H5/H5", b, 2H), 11.34 
(OH, s, 1H) 11.51 ppm (OH, s, 1H); 13C-NMR (CD2Cl2): δ 36.05 (C*), 55.75 (OCH3), 104.80/106.32 
(C3/C3"), 114.32 (C3'/C5'), 117.02 (C10/C10"), 117.13 (C8/C8"), 124.66 (C5/C5"), 125.40 (C6/C6"), 
127.65 (C1'), 128.19 (C2'/C6'), 133.39 (C7/C7"), 152.89/153.01 (C9/C9"), 159.04 (C4'), 164.88/166.20 
(C4/C4"), 167.42/169.77 ppm (C2/C2"); ES-MS m/z 443 [M−H]. Elemental analysis. Calc. for 
C26H18O7 (%): C 70.59, H 4.10, Found: C 70.26, H 4.41. 
3,3'-(4-Methyltiobenzylidene)-bis-[4-hydroxycoumarin] (11) [14]. Yield 70%; mp 258.7 °C; IR (KBr) 
(ν, cm−1): 2916 (CH), 2114 (C–S), 1726 (C=O), 1658 (C=C–C=O), 1612, 1566, 1492, 1454 (C=C), 
1400 (CH3), 1198 (OH); 1H-NMR (DMSO-d6): δ 2.42 (SCH3, s, 3H), 6.28 (H*, s, 1H), 7.08 (H2'/H6', 
m, 2H), 7.12 (H3'/H5', m, 2H), 7.29 (H6/H6", m, 2H), 7.33 (H8/H8", m, 2H), 7.57 (H7/H7", m, 2H), 
7.87 ppm (H5/H5", dd, J = 7.9, 1.4, 2H); 13C-NMR (DMSO-d6): δ 15.03 (SCH3), 35.63 (C*), 103.80 
(C3/C3"), 115.77 (C8/C8"), 118.57 (C10/C10"), 123.43 (C6/C6"), 123.94 (C5/C5"), 126.04 (C3'/C5'), 
127.40 (C2'/C6'), 131.56 (C7/C7"), 134.30 (C4'), 137.74 (C1'), 152.29 (C9/C9"), 164.63 (C2/C2"), 
166.06 ppm (C4/C4"); ES-MS m/z 459 [M−H]. 
3,3'-(4-Dimethylaminobenzilidene)-bis-[4-hydroxycoumarin] (12) [11,14]. Yield 65.6%; mp 205.8 °C; 
IR (KBr) (ν, cm−1): 2882 (CH), 1774 (C=O), 1665 (C=C–C=O), 1606, 1568, 1498, 1454 (C=C), 1440 
(CH3N), 1264 (C–N), 1194 (OH); 1H-NMR (DMSO-d6): δ 3.13 (CH3, s, 6H), 6.28 (H*, s, 1H), 7.24 
(H6/H6", m, 2H), 7.24 (H2'/H6', m, 2H), 7.27 (H8/H8", dd, J = 8.1, 1.1, 2H), 7.39 (H3'/H5', m, 2H), 
7.52 (H7/H7", m, 2H), 7.81 ppm (H5/H5", dd, J = 7.8, 1.4, 2H); 13C-NMR (DMSO-d6): δ 35.92 (C*), 
45.43 (CH3), 103.04 (C3/C3"), 115.58 (C8/C8"), 119.46 (C10/C10"), 119.66 (C3'/C5'), 123.00 
(C6/C6"), 124.10 (C5/C5"), 128.15 (C2'/C6'), 131.14 (C7/C7"), 140.82 (C4'), 152.51 (C9/C9"), 164.42 
(C2/C2"), 167.60 ppm (C4/C4"); ES-MS m/z 456 [M−H]. Elemental analysis. Calc. for C27H21O6N: C 
71.20, H 4.65, N 3.08, Found: C 71.23, H 4.61, N 3.11. 
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3,3'-(3,4-Dihydroxybenzylidene)-bis-[4-hydroxycoumarin] (13). Yield 70%; mp 227.5 °C; IR (KBr)  
(ν, cm−1): 3568 (OH), 2898 (CH), 1658 (C=O), 1604, 1566, 1498, 1452 (C=C), 1222 (OH); 1H-NMR 
(DMSO-d6): δ 6.20 (H*, s, 1H), 6.39 (H6', m, 1H), 6.55 (H2', m, 1H), 6.58 (H5', d, J=8.1, 1H), 7.33 
(H6/H6", m, 2H), 7.37 (H8/H8", d, J = 7.6, 2H), 7.60 (H7/H7", m, 2H), 7.91 ppm (H5/H5", dd, J = 7.9, 
1.5, 2H); 13C-NMR (DMSO-d6): δ 35.21 (C*), 104.45 (C3/C3"), 114.22 (C2'), 115.33 (C5'), 115.92 
(C8/C8"), 117.38 (C6'), 117.84 (C10/C10"), 123.76 (C6/C6"), 123.86 (C5/C5"), 130.17 (C1'), 131.86 
(C7/C7"), 143.19 (C4'), 144.89 (C3'), 152.12 (C9/C9"), 164.76/164.93 ppm (C2/C2"/C4/C4"); ES-MS 
m/z 445 [M−H]. Elemental analysis. Calc. for C25H16O8N: C 67.75, H 3.61, Found: C 67.65, H 3.66. 
3,3'-(2,5-Dimethoxybenzylidene)-bis-[4-hydroxycoumarin] (14). Yield 72%; mp 181.6 °C; IR (KBr) 
(ν, cm−1): 2960 (CH); 1656 (C=C–C=O), 1602, 1568, 1500, 1452 (C=C), 1416 (OCH3), 1186 (OH); 
1154 (CO); 1H-NMR (DMSO-d6): δ 3.51 (2'-OCH3, s, 3H), 3.62 (5'-OCH3, s, 3H), 6.22 (H*, s, 1H), 
6.71 (H6', s, 1H), 6.73 (H4', m, 1H), 6.81 (H3', m, 1H), 7.31 (H6/H6", m, 2H), 7.34 (H8/H8", d, J = 7.3, 
2H), 7.57 (H7/H7", m, 2H), 7.90 ppm (H5/H5", dd, J = 7.9, 1.5, 2H); 13C-NMR (DMSO-d6): δ 33.02 
(C*), 55.13 (2'-OCH3), 56.13 (5'-OCH3), 104.63 (C3/C3"), 110.03 (C4'), 111.84 (C3'), 115.90 
(C8/C8"), 115.96 (C6'), 117.77 (C10/C10"), 123.61/123.63 (C5/C5"/C6/C6"), 130.23 (C1'), 131.57 
(C7/C7"), 151.63 (C2'), 152.03 (C9/C9"), 152.79 ppm (C5'), 163.96/164.03 (C2/C2"/C4/C4"); ES-MS 
m/z 473 [M−H]. Elemental analysis. Calc. for C27H20O8: C 68.64, H 4.27, Found: C 68.52, H 4.30. 
3,3'-(4-Hydroxy-3-methoxy-5-nitrobenzylidene)-bis-[4-hydroxycoumarin] (15). Yield 70%; mp 199.6 °C; 
IR (KBr) (ν, cm−1): 3274 (OH), 2868 (CH), 1778 (C=O), 1658 (C=C–C=O), 1608, 1566, 1496, 1454 
(C=C); 1350, 1634 (NO2) 1416 (OCH3); 1198 (OH) 1152 (CO); 1H-NMR (DMSO-d6): δ 3.67 (OCH3, 
s, 3H), 6.23 (H*, t, J = 1.0, 1H), 7.01 (H2', m, 1H), 7.18 (H6', m, 1H), 7.29 (H6/H6", m, 2H), 7.32 
(H8/H8", d, J = 7.3, 2H), 7.56 (H7/H7", m, 2H), 7.87 ppm (H5/H5", dd, J = 7.8, 1.5, 2H); 13C-NMR 
(DMSO-d6): δ 35.81 (C*), 56.58 (OCH3), 103.35 (C3/C3"), 113.57 (C6'), 115.80 (C8/C8"), 115.88 
(C2'), 118.73 (C10/C10"), 123.40 (C6/C6"), 123.99 (C5/C5"), 131.55 (C7/C7"), 132.16 (C1'), 136.45 
(C5'), 140.89 (C4'), 149.16 (C3'), 152.37 (C9/C9"), 164.36 (C2/C2"), 166.45 ppm (C4/C4"); ES-MS 
m/z 504 [M−H]. Elemental analysis. Calc. for C26H17O10N: C 62.03, H 3.40 N 2.78, Found: C 62.33, H 
3.34, N 2.89. 
3-[6-Oxo-(1H)-benzopyrano[4,3-b]-(1)10-hydroxybenzopyran-7-yl]-4-hydroxycoumarin (16) [17,18]. 
Yield 82%; mp 241.7 °C; IR (KBr) (ν, cm−1): 2958 (CH), 1616, 1570, 1488, 1456 (C=C), 1230 (C=O); 
1H-NMR (DMSO-d6): δ 5.74 (H*, s, 1H), 7.14 (H5', m, 1H), 7.20 (H6', m, 1H), 7.32 (H8, m, 1H), 7.34 
(H4', m, 1H), 7.35 (H3', m, 1H), 7.36 (H6, m, 1H), 7.46 (H8", m, 1H), 7.49 (H6", m, 1H), 7.60 (H7, m, 
1H), 7.71 (H7", dd, J = 7.5, 1.7, 1H), 8.03 (H5, m, 1H), 8.11 (H5", dd, J = 7.9, 1.4, 1H), 12.21 ppm 
(OH, b, 1H); 13C-NMR (DMSO-d6): δ 28.64 (C*), 100.60 (C3), 106.14 (C3"), 113.78 (C10), 
116.08/116.22/116.22 (C3'/C8"/C10"), 116.47 (C8), 122.20 (C1'), 122.61 (C5), 123.72 (C5"), 123.97 
(C6"), 124.55 (C6), 125.35 (C5'), 128.36 (C4'), 128.62 (C6'), 132.19 (C7"), 132.50 (C7), 149.16 (C2'), 
151.97 (C9), 152.17 (C9"), 156.24 (C4), 160.38 (C2), 160.66 ppm (C2"); ES-MS m/z 411 [M−H]. 
3-[6-Oxo-(1H)-18-bromobenzopyrano[4,3-b]benzopyran-7-yl]-4-hydroxycoumarin (17). Yield 72%; 
mp 296 °C; IR (KBr) (ν, cm−1): 3274 (OH); 2886 (CH); 1772 (C=C–C=O), 1610, 1570, 1558, 1496, 
(C=C), 1220 (CO), 586 (C–Br); 1H-NMR (DMSO-d6): δ 5.71 (H*, s, 1H), 7.31 (H6', d, J = 1.8, 1H), 
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7.32 (H8, m, 1H), 7.34 (H3', d, J = 8.7, 1H), 7.36 (H6, m, 1H), 7.45 (H8", m, 1H), 7.49 (H6", m, 1H), 
7.52 (H4', m, 1H), 7.61 (H7, m, 1H), 7.71 (H7", m, 1H), 8.03 (H5, b, 1H), 8.11 (H5", dd, J = 7.9, 1.4, 
1H), 12.19 ppm (OH, b, 1H). ES-MS m/z 488 [M−H]. Elemental analysis. Calc. for C25H13O6Br: C 
61.9, H 2.68, Found: C 61.7, H 2.68. 
3-[6-Oxo-(1H)-16-methoxybenzopyrano[4,3-b]benzopyran-7-yl]-4-hydroxycoumarin (18). Yield 73%; 
mp 278.3 °C; IR (KBr) (ν, cm−1): 3480 (OH); 2906 (CH); 1824 (C=O); 1662 (C=C–C=O), 1620, 1586, 
1496, 1460 (C=C), 1440 (OCH3), 1188 (OH), 990 (CO); 1H-NMR (DMSO-d6): δ 3.93 (OCH3, s, 3H), 
5.72 (H*, s, 1H), 6.75 (H6', m, 1H), 7.02 (H4', m, 1H), 7.08 (H5', m, 1H), 7.33 (H8, m, 1H), 7.36 (H6, 
m, 1H), 7.45 (H8", d, J = 8.2, 1H), 7.51 (H6", m, 1H), 7.60 (H7, m, 1H), 7.70 (H7", dd, J = 7.5, 1.7, 
1H), 7.99 (H5", dd, J = 7.8, 1.5, 1H), 8.06 (H5, m, 1H), 12.26 ppm (OH, b, 1H); 13C-NMR (DMSO-d6): 
δ 28.67 (C*), 56.04 (OCH3), 100.38 (C3), 104.02 (C3"), 111.18 (C4'), 113.92 (C10), 116.06 (C10"), 
116.26 (C8), 116.54 (C8"), 119.66 (C6'), 122.38 (C5"), 122.87 (C1'), 123.8 (C5), 123.99 (C6), 124.65 
(C6"), 125.14 (C5'), 132.23 (C7), 132.47 (C7"), 138.64 (C2'), 147.29 (C3'), 151.93 (C9"), 152.16 (C9), 
155.94 (C4"), 160.41/160.65 ppm (C2/C2"/C4); ES-MS m/z 441 [MH]+. Elemental analysis. Calc. for 
C26H16O7: C 69.77, H 3.66, Found: C 69.85, H 3.84. 
3-[6-Oxo-(1H)-18-nitrobenzopyrano[4,3-b]benzopyran-7-yl]-4-hydroxycoumarin (19). Yield 69%; mp 
315.7 °C; IR (KBr) (ν, cm−1): 3318 (OH); 2854 (CH), 1818 (C=O); 1675 (C=C–C=O), 1610, 1586, 
1498, 1456 (C=C), 1314, 1560 (NO2), 1190 (OH); 1H-NMR (DMSO-d6): δ 5.79 (H*, b, 1H), 7.28 (H8, 
b, 1H), 7.34 (H6, b, 1H), 7.46 (H8", d, J = 8.3, 1H), 7.50 (H6", m, 1H), 7.58 (H7, b, 1H), 7.60 (H3', d, 
J = 9.0, 1H), 7.71 (H7", m, 1H), 8.01 (H6', d, J = 2.8, 1H), 8.03 (H5, b, 1H), 8.13 (H5", dd, J = 7.9, 
1.6, 1H), 8.18 (H4', dd, J = 9.0, 2.8, 1H), 12.49 ppm (OH, b, 1H); ES-MS m/z 456 [M−H]. Elemental 
analysis. Calc. for C25H13O8N: C 65.93, H 2.88, N 3.07, Found: C 66.02, H 2.96, N 3.04. 
3-[6-oxo-(1H)-15,17-dimethoxybenzopyrano[4,3-b]benzopyran-7-yl]-4-hydroxycoumarin (20). Yield 
68%; mp 287.9 °C; IR (KBr) (ν, cm−1): 2940 (CH), 1654 (C=C–C=O), 1596, 1570, 1494, 1456 (C=C), 
1438 (OCH3), 1276 (CO), 1190 (OH); 1H-NMR (DMSO-d6): δ 3.67 (6'-OCH3, s, 3H), 3.80 (4'-OCH3, 
s, 3H), 5.57 (H*, b, 1H), 6.36 (H5', d, J = 2.4, 1H), 6.59 (H3', d, J = 2.4, 1H), 7.27 (H8, d, J = 8.1, 1H), 
7.34 (H6, m, 1H), 7.44 (H8", m, 1H), 7.48 (H6", m, 1H), 7.57 (H7, m, 1H), 7.69 (H7", dd, J = 7.5, 1.7, 
1H), 8.00 (H5, m, 1H), 8.10 (H5", dd, J = 7.9, 1.4, 1H), 11.84 ppm (OH, b, 1H); 13C-NMR (DMSO-d6): 
δ 24.97 (C*), 55.47 (4'-OCH3), 55.95 (6'-OCH3), 93.51 (C3'), 95.40 (C5'), 100.79 (C3), 102.59 (C1'), 
104.65 (C3"), 113.73 (C10"), 115.97 (C8), 116.32 (C10), 116.44 (C8"), 122.61 (C5"), 123.79 (C5), 
123.79 (C6), 124.47 (C6"), 131.80 (C7), 132.43 (C7"), 150.73 (C2'), 151.94 (C9"), 152.11 (C9), 
156.27 (C4"), 157.82 (C6'), 159.71 (C4'), 160.31/160.40/160.80 ppm (C2/C2"/C4); ES-MS m/z 471 
[M−H]. Elemental analysis. Calc. for C27H18O8: C 68.93, H 3.86, Found: C 68.85, H 3.92. 
4.3. Crystal Structure Determination of 7, 9, 16 and 18 
Crystals suitable for X-ray single crystal structure study were grown by slow evaporation from 
dichloromthane for 7 and 18, toluene for 9 and ethanol solution for 16. The intensities were collected 
on an Oxford Diffraction Xcalibur2 diffractometer with a Sapphire 3 CCD detector using graphite-
monochromated MoKα radiation (λ = 0.71073 Å) and ω scan-mode at 295 K. CrysAlisPro [22] 
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program was used for data collection and processing. The intensities were corrected for absorption 
using the multi-scan absorption correction method [22]. The crystal structures were solved by direct 
methods [23] and all non-hydrogen atoms were refined anisotropically by full-matrix least-squares 
calculations [23] based on F2 using the programs integrated in WinGX [24] program package. The 
hydrogen atoms attached to the O3 and O3’ atoms in 7 and 9, O3A and O3B atoms in 16 and O3 atom 
in 18 were found in a difference Fourier map and are refined with O-H distance restraint of 0.82 Å. All 
other hydrogen atoms were treated using appropriate riding models, with SHELXL97 defaults [23]. 
Fluorine atoms of trifluoromethyl group in 7 are heavily disordered and restraints on anisotropic 
displacement parameters were therefore used in their refinement. The C29 and C31 atoms of ethanol 
molecules in 16 are disordered with the site occupancy factors refined to 0.62(3)/0.38(3) and 
0.52(3)/0.48(3) ratio, respectively. Details of crystal data, data collection and refinement parameters 
are given in Table 3. PLATON [25] program was used for structure analysis and molecular and crystal 
structure drawings preparation. CCDC 818091-818094 contain the supplementary crystallographic 
data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic 
Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Table 3. X-ray crystallographic data for compounds 7, 9, 16 and 18. 
Compound 7 9 16 18 
Formula C26H15F3O6 C25H15NO8 C54H42O15 C26H16O7 
Formula weight 480.38 457.38 930.88 440.39 
Crystal size [mm] 0.44 × 0.24 × 0.22 0.28 × 0.24 × 0.20 0.62 × 0.35 × 0.48 × 0.14 × 0.09 
Crystal colour, shape colourless, block colourless, block colourless, prism colourless, prism 
Crystal system monoclinic monoclinic monoclinic triclinic 
Space group P 21/c C 2/c P 21/c P⎯1 
Unit cell dimensions     
a [Å] 10.4430(4) 34.4429(19) 18.6160(10) 9.4927(4) 
b [Å] 10.4031(4) 7.5448(3) 15.2918(5) 9.7660(4) 
c [Å] 20.1801(9) 16.8941(9) 17.7112(10) 11.8741(5) 
α [°] 90 90 90 66.322(4) 
β [°] 91.423(3) 112.749(6) 115.484(7) 73.399(4) 
γ [°] 90 90 90 83.084(3) 
V [Å3] 2191.68(15) 4048.7(3) 4551.3(4) 966.09(7) 
Z 4 8 4 2 
Dcalc. [g cm−3] 1.456 1.501 1.359 1.514 
μ [mm−1] 0.120 0.114 0.100 0.111 
θ range [°] 4.14 to 26.00 4.19 to 26.00 4.16 to 26.00 4.21 to 26.00 
Collected reflections No. 17378 21957 41605 13789 
Independent reflections No. / Rint. 4298 / 0.0279 3970 / 0.0229 8906 / 0.0477 3777 / 0.0315 
Reflections number I ≥ 2σ(I) 2649 2694 5836 2341 
Data / restraints / parameters 4298 / 20 / 324 3970 / 2 / 315 8906 / 6 / 666 3777 / 1 / 303 
Goodness-of-fit on F2 0.999 1.010 1.020 0.997 
R [I ≥ 2σ(I)] / R [all data] 0.0611 / 0.0926 0.0391 / 0.0587 0.0453 / 0.0878 0.0390 / 0.0707 
wR [I ≥ 2σ(I)] / wR [all data] 0.2004 / 0.2150 0.1103 / 0.1158 0.1039 / 0.1305 0.0954 / 0.1043 
Max./min. elect. density [e Å−3] 0.543 / -0.425 0.388/ −0.186 0.189 / −0.270 0.216 / −0.174 
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4.4. Virological Assays 
The antiviral assays, other than the anti-HIV assays, were based on inhibition of virus-induced 
cytopathic effect in human lung fibroblast [herpes simplex virus type 1 (HSV-1) [strain KOS], herpes 
simplex virus type 2 (HSV-2) [strain G], vaccinia virus (VV) and vesicular stomatitis virus (VSV)], 
African green monkey kidney (Vero, parainfluenza-3, reovirus-1, Sindbis, Coxsackie B4, and Punta 
Toro virus), human cervix carcinoma (vesicular stomatitis virus, Coxsackie virus B4 and respiratory 
syncytial virus (RSV)), feline Crandell-Rees kidney (CRFK) (feline herpes virus, feline corona virus 
(FIPV)) or Madin-Darby canine kidney (MDCK) (influenza A [H1N1; H3N2] and influenza B) cell 
cultures. Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus 
(1 CCID50 being the virus dose to infect 50% of the cell cultures) in the presence of varying 
concentrations (100, 40, 8, 1.6 and 0.32 µM) of the test compounds. Viral cytopathicity was recorded 
as soon as it reached completion in the control virus-infected cell cultures that were not treated with 
the test compounds. The anti-HIV activity and cytotoxicity of the compounds were evaluated against 
wild-type HIV-1 strain IIIB in MT-4 cell culture using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method. MT-4 cells were suspended in culture medium at 1 × 105 
cells/mL and infected with HIV at a multiplicity of infection of 0.02. Immediately after viral infection, 
100 µL of the cell suspension was placed in each well of a flat-bottomed microtiter tray containing 
various concentrations of the test compounds. After four days of incubation at 37 °C, the number of 
viable cells was determined using the MTT method. Compounds were tested in parallel for cytotoxic 
effects in uninfected MT-4 cells. 
4. Conclusions 
A series of the benzylidene-bis-(4-hydroxycoumarin) derivatives 1–15 and fused benzopyranocoumarin 
derivatives 16–20 were synthesized and evaluated for their antiviral activities on a broad panel of DNA 
and RNA viruses. X-ray crystal structure analysis of 4-trifluoromethylphenyl- and 2-nitrophenyl 
derivatives 7 and 9 revealed intramolecular hydrogen bonding between hydroxyl and carbonyl oxygen 
atoms of two 4-hydroxycoumarin moieties resulting in the formation of two eight-membered rings. 
Accordingly, two 4-hydroxycoumarin moieties in compounds 7 and 9 are anti-disposed. The  
4-bromobenzylidene derivative of bis(4-hydroxycoumarin) (3) exerted some inhibitory activity against 
HSV-1 (KOS), HSV-2 (G), vaccinia virus and HSV-1 TK- KOS (ACVr) in the range of 9–12 μM at 
minimum cytotoxic concentration (MCC) greater than 20 μM, whereas the compounds 4–6, 8, and 20 
exhibited rather pronounced anti-Feline Herpes Virus activity (EC50 = 5–8.1 μM) but with MCC at 
only 4-7-fold higher than EC50 values. 
Electronic Supplementary Information (ESI)  
Tables S1 with hydrogen-bonded geometries, Figures S1-S4 presenting hydrogen bonds for 
compounds 7, 9, 16 and 18. 
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